Search

Benznidazole

Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. … [L939] It is the first treatment made available in the United States for Chagas disease.

Zoledronic acid

[L13712,L13715,L13721] Zoledronic acid was first described in the literature in 1994.[A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712]

Oxacillin

An antibiotic similar to [flucloxacillin] used in resistant staphylococci infections.

Aluminum sulfate

Al is found in materials used in the pharmaceutical industry, and in manufactured foodstuffs, cosmetics, and tap water. … Aluminum (Al) is ubiquitous and represents the third most common element in the Earth’s crust. It most commonly exists in a combined state with various other elements.

Prucalopride

[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

four drug substances contained in each dose of vaccine. … [A253277] Several serogroups of _N. meningitidis_ - A, B, C, Y, and W-135 - known to cause meningococcal infections have been identified.

(+)-menthol

Lunsotogene parvec

Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission

Cevimeline

Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.

Tetrabenazine

FDA approved on August 15, 2008. … A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders.